Sexology Research Group, Gynaecology Clinic, Department of General Surgery and Medical Surgical Specialties, School of Medicine, University of Catania, Catania, Italy.
Department of Woman, Child and General and Specialised Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Eur J Contracept Reprod Health Care. 2020 Aug;25(4):251-258. doi: 10.1080/13625187.2020.1760240. Epub 2020 May 21.
The aims of the study were to investigate the effect of a subcutaneous etonogestrel-containing contraceptive implant on the quality of life (QoL) and sexual function of women who had undergone termination of an unplanned pregnancy.
At pregnancy termination 140 women received contraceptive counselling on the etonogestrel implant. The Short Form-36 questionnaire, the Female Sexual Function Index and the Female Sexual Distress Scale were used to investigate, respectively, the QoL, sexual function and sexual distress of the women at baseline and at 6, 12, 24 and 36 months of follow-up.
The study group comprised 86 (61.4%) women who chose to use the contraceptive implant. The control group comprised 28 (20.0%) women who chose to use short-acting reversible contraception (SARC) and 26 (18.6%) women who chose not to use hormonal contraception. In the women not using hormonal contraception there were 23 (88.5%) unintended pregnancies before the end of the 3 year study period. QoL, sexual function and sexual distress improved in the study group from the 6 months follow-up until the end of the study ( < 0.001). QoL ( < 0.02) and sexuality ( < 0.001) gradually improved in the control group after 24 and 12 months of follow-up, respectively. None of the women using the etonogestrel implant became pregnant during the study. Inter-group analysis showed better improvement in QoL, sexual function and sexual distress in the study group than in the control group from 6 months ( < 0.004) until the end of the study ( < 0.001).
Compared with SARC and non-hormonal contraception, the contraceptive implant promoted better QoL and sexuality in users and reduced the incidence of unplanned pregnancy. However, the women who opted for SARC or non-hormonal contraception did so because of the lower cost compared with that of the contraceptive implant.
本研究旨在探讨皮下埋植依托孕烯避孕针对终止意外妊娠女性生活质量（QoL）和性功能的影响。
在终止妊娠时，140 名女性接受了依托孕烯埋植避孕针的避孕咨询。采用简短健康调查问卷（SF-36）、女性性功能指数（FSFI）和女性性功能障碍简表（FSDS）分别在基线和 6、12、24 和 36 个月随访时评估女性的 QoL、性功能和性功能障碍。
研究组包括 86 名（61.4%）选择使用避孕埋植剂的女性。对照组包括 28 名（20.0%）选择使用短效可逆避孕（SARC）的女性和 26 名（18.6%）选择不使用激素避孕的女性。在未使用激素避孕的女性中，有 23 名（88.5%）在 3 年研究期间发生了意外妊娠。从 6 个月随访开始，研究组的 QoL、性功能和性功能障碍均得到改善，直至研究结束（ < 0.001）。对照组分别在 24 个月和 12 个月随访后 QoL（ < 0.02）和性行为（ < 0.001）逐渐改善。在研究期间，没有使用依托孕烯避孕针的女性怀孕。组间分析显示，从 6 个月（ < 0.004）开始至研究结束（ < 0.001），研究组在 QoL、性功能和性功能障碍方面的改善均优于对照组。
与 SARC 和非激素避孕相比，避孕埋植剂可改善使用者的 QoL 和性功能，并降低意外妊娠的发生率。然而，选择 SARC 或非激素避孕的女性这样做是因为其成本低于避孕埋植剂。
